Hybritech plans exit from MoAb imaging arena

Article

One of the pioneers in monoclonal antibody research has droppedout of the in vivo imaging market. Hybritech of San Diego is phasingout the development of its Hybri-CEAker product, which was beingdeveloped to image colorectal cancer. Hybritech's board

One of the pioneers in monoclonal antibody research has droppedout of the in vivo imaging market. Hybritech of San Diego is phasingout the development of its Hybri-CEAker product, which was beingdeveloped to image colorectal cancer.

Hybritech's board of directors voted last month to discontinuethe company's discovery and development efforts in radioimmunotherapyand in vivo imaging. The projects are to be terminated by year-end.

Also last month, Hybritech's parent company, Eli Lilly of Indianapolis,IN, announced plans to cut 4000 salaried and contract jobs throughearly retirements and reassignments. The move reportedly is partof a broad reexamination by Lilly of its business pursuits.

Hybritech staff refused comment on whether the decision byHybritech to exit the in vivo market was part of this reexamination,referring inquiries to the parent company. It was learned, however,that the decision to exit the imaging market was precipitatedby Hybritech's electing to abandon cancer therapeutics.

Donald W. Grimm, Hybritech chairman, said in a prepared statementthat management was no longer able to justify the continued financialinvestment in cancer therapeutics.

"Without a commitment to therapeutic research, a continuedinvestment in imaging, particularly to create the infrastructurenecessary to build an imaging business, cannot be sustained,"he said.

Hybritech, like many imaging agent developers, had been pursuingthe matched-pair approach, in which a delivery system, such asa monoclonal antibody or peptide, is matched to one isotope forimaging and another for therapy. Economies of scale in developmentand marketing for the imaging and therapy markets increase thevalue of the effort.

"But when it was no longer in its strategic directionto pursue in vivo therapeutics, that set off kind of a chain reaction,in which the investment needed to (continue pursuing) the in vivoimaging product was too high," said David Pomfret, a spokespersonfor Eli Lilly.

The decision to abandon radioimmune therapy and in vivo imagingcomes at a time when the business potential for targeted imagingagents, such as monoclonal antibodies and peptides, appears onthe verge of being realized. One agent, OncoScint from Cytogenof Princeton, NJ, is on the market and others are expected soon.

Hybri-CEAker, which targets the carcinoembryonic antigen (CEA),although promising, has been in the Food and Drug Administrationreview process since 1989 and shows no signs of being clearedfor market in the near future. As Hybritech concludes its in vivoimaging and therapeutics efforts, it is actively searching forcompanies interested in licensing the technology.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.